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Abstract 
Objective: RalA and RalB GTPases are important regulators of cell growth, cancer 
metastasis and granule secretion. The purpose of this study was to determine the role 
of Ral GTPases in platelets with the use of platelet specific gene-knockout (KO) mouse 
models. 
Approach and Results: This study shows that platelets from double knockout mice 
(DKO), in which both GTPases have been deleted, show markedly diminished (approx. 
85 % reduction) P-selectin translocation to the surface membrane, suggesting a critical 
role in α-granule secretion. Surprisingly however there were only minor effects on 
stimulated release of soluble α- and δ-granule content, with no alteration in granule 
count, morphology or content. In addition, their expression was not essential for platelet 
aggregation or thrombus formation. However, absence of surface P-selectin caused a 
marked reduction (approx. 70 %) in platelet-leukocyte interactions in blood from RalAB 
DKO mice, suggesting a role for platelet Rals in platelet-mediated inflammation.  
Conclusions: Platelet Ral GTPases primarily control P-selectin surface expression, in 
turn regulating platelet-leukocyte interaction. Ral GTPases could therefore be important 
novel targets for the selective control of platelet-mediated immune cell recruitment and 
inflammatory disease. 
 
 
Nonstandard Abbreviations and Acronyms 
α-granule Alpha granule 
δ-granule  Dense granule 
CRP-XL Cross linked collagen related peptide 
PAR4-AP Protease-activated receptor 4-activating peptide 
PF4 Platelet factor 4 
TGF-β  Transforming growth factor beta 
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Introduction 
Ral GTPases, RalA and RalB, are Ras-like small GTPases that are important mediators 
of tumour growth and metastasis, with Ral inhibitor compounds currently being 
developed as novel anti-cancer agents1-3. In addition, they have key roles to play in 
membrane trafficking and secretion via interactions with their effector, the exocyst 
complex4,5. Widely expressed in human tissues, the exocyst is an octameric protein 
complex involved in tethering secretory vesicles to plasma membranes, preceding N-
ethylmaleimide–sensitive factor attachment protein receptor (SNARE) complex 
formation and exocytosis5,6. In platelets, regulatory GTPases such as Rab27b, RhoA/G 
and Rap1b all play major roles in platelet function, acting as molecular switches in 
signalling pathways, themselves being regulated by guanine exchange factors (GEFs) 
and GTPase activating proteins (GAPs)7-9. Rals have been shown to be expressed in 
platelets, but are yet to be extensively investigated in these cells.  
Platelet activation at sites of vascular damage leads to the release of over 300 bioactive 
molecules from distinct secretory granules10,11. Dense (δ) granules predominantly 
contain small molecules with platelet-activating properties, aiding recruitment of 
platelets to a growing thrombus12. The contents and roles of alpha (α) granules are 
more varied, with studies highlighting roles for α-granule releasates in immune 
responses and wound healing, as well as angiogenesis and tumour metastasis13. 
Importantly, α-granules also express cell adhesion molecules such as P-selectin on 
their membranes which translocate to the platelet membrane upon granule fusion, 
mediating interaction with leukocytes - regulating their extravasation into tissues14,15. As 
the functions associated with platelet releasates are so varied, platelet secretion is a 
tightly regulated process16,17. 
Little is known about the role of platelet Ral GTPases. Previous studies have shown that 
both RalA/B become activated upon platelet stimulation in a Ca2+-dependent manner, 
and the use of functional blocking antibodies in a permeabilised platelet system 
highlighted roles for Rals in δ-granule secretion via exocyst interactions18,19. However, 
due to a lack of knockout models and the limitations associated with the use of 
permeabilised platelet systems, elucidating fully the roles of platelet Rals has not 
previously been possible. 
In this study we have generated the first murine platelet-specific knockouts for RalA, 
RalB and both together (RalAB), to definitively investigate the roles of these GTPases in 
platelets. Results show that the presence of at least one Ral isoform is necessary for P-
selectin expression on the platelet membrane, with RalAB double knockout (DKO) 
platelets showing an 85% reduction in P-selectin expression in response to platelet 
stimulation. Surprisingly however, release of α-granule cargo is largely unaltered in the 
RalAB DKO, pointing to the possibility that Ral GTPases do not control all aspects of α-
granule secretion. Furthermore, δ-granule secretion was only marginally reduced in the 
RalAB DKO, with no significant effect observed in aggregation or thrombus formation 
assays. The markedly diminished P-selectin exposure in the absence of RalAB leads to 
a substantial reduction in platelet-leukocyte interactions. The Pf4-Cre+ RalA/Bflox mice 
also show a delay in the onset of dextran sulfate sodium (DSS)-induced ulcerative 
colitis symptoms in vivo. Taken together these results suggest that platelet Rals may 
contribute to platelet-mediated immune responses and targeting them may provide a 
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novel and selective approach to the treatment of certain inflammatory diseases, while 
also providing caution regarding the use of Ral inhibitors in the treatment of cancer2. 
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Materials & Methods 
 
Materials -  RalA and RalB rabbit monoclonal antibodies were from Cell Signalling 
Technology (Beverly, USA) supplied by NEB (New England Biolabs) (Hitchin, UK) 
[#3526 and #3523]. RalA mouse monoclonal antibody was from BD (Becton Dickson) 
Biosciences (Oxford, UK) [#610222]. EXOC2/Sec5 antibody was from Protein 
Technologies (Manchester, UK) [#12751-1-AP]. EXOC3/Sec6 antibody was from EMD 
Millipore (Billerica, USA) [#559240]. EXOC4/Sec8 antibody was from Abcam 
(Cambridge, UK) [#ab13254]. FITC-conjugated GPVI [#M011-1], GP1b [#M040-1], 
Integrin α2 [#M071-1], P-selectin/CD62P [#M130-1] and PE-conjugated JON/A anti-
integrin αIIbβ3 [#M023-2] were from Emfret Analytics (Eibelstadt, Germany). FITC-
conjugated CD41 antibody was from Bio-Rad (Hemel Hempstead, UK) [#MCA2245F] 
with the PE-conjugated CD45 antibody supplied by BioLegend (London, UK) [#30-F11]. 
P-selectin and vWf antibodies were from Santa Cruz bioscience (Texas, USA) [#SC-
6943 and #H-300] alongside control cell lysates for PC-12 [#SC-2250], NRK [#SC-
364199] and RPE-1 [#SC-24771]. ActinGreen F-actin probe was from Life Technologies 
(Warrington, UK) [#R37110]. OneComp eBeads were from eBioscience (Hatfield, UK) 
[01-1111-42]. CRP-XL (collagen related peptide) was provided by Professor Richard 
Ferndale (University of Cambridge, UK). Chrono-lume ATP detection kit was from 
Labmedics (Manchester, UK) [#P/N 395]. GST (glutathione sepharose transferase) 
beads were from GE healthcare (Little Chalfont, UK) [#17075601], with the GST-
RalBP1 (Ral binding protein 1)/RLIP76 construct being generously gifted by Ingrid 
Verlaan-Klink (Utrecht University, Netherlands). RalA Q75L [#19719], RalA S31N 
[#19718], RalB Q72L [#19721], RalB S28N [#19722] constructs1 were supplied by 
Addgene (Cambridge, USA). NuPAGE LDS Sample buffer was from Life Technologies 
(Warrington, UK) [#NP0008]. Western blotting equipment was from Bio-Rad (Hemel 
Hempstead, UK) [#1703930] with ECL (enhanced chemiluminescent) detection 
reagents from GE healthcare (Little Chalfont, UK) [#RPN2232] and PVDF 
(polyvinylidene difluoride) transfer membrane (Immobilon P/FL) from Millipore 
(Nottingham, UK) [#IPVH00010]. Ibidi slides [#80661] and elbow luers [#10802] were 
from Thistle Scientific (Glasgow, UK). Horm fibrillary collagen was from Takeda Pharma 
(Linz, Austria) [#1128818]. Ketamine was from Pfizer (Kent, UK) [#EN-3179]. Xylazine 
was from Bayer (Reading, UK) [#1040032]. DyLight 488-conjugated anti-GPIbβ 
antibody was from Novus Biologicals (Abingdon, UK) [#NB100-63790G]. 5 mL round-
bottom polystyrene FACS tubes were supplied by BD Biosciences (Oxford, UK) 
[#352235]. Red blood cell lysis (RBC) buffer was from Roche (Basel, Switzerland) 
[#11814389001]. Mouse TGF-β [#DY1679] and PF4 ELISA kits [#DY595], as well as 
angiogenesis microarray kits [#ARY015] were from R&D Systems (Abingdon, UK). 
ProLong Diamond Antifade mountant was from Life Technologies (Warrington, UK) 
[#P36965]. Dextran sulfate sodium (DSS) was provided by KWS Biotest (Portishead, 
UK). All agonist preparations were made up in modified HEPES-Tyrode’s unless 
otherwise stated, with unlisted reagents all supplied by Sigma Aldrich (Dorset, UK). 
Mice - A colony of RalAflox/flox and RalBflox/flox mice were generously provided by 
Professor Chris Marshall, Institute of Cancer Research, London20. Mice were crossed 
with Cre-PF4 mice to create RalAflox/flox:Cre+ (RalA KO), RalAflox/flox:Cre- (RalA WT [Wild-
type]), RalBflox/flox:Cre+ (RalB KO) and RalBflox/flox:Cre- (RalB WT) mice. Subsequently, 
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RalAflox/flox:Cre+ mice were crossed with RalBflox/flox:Cre- mice to generate 
RalAflox/flox:RalBflox/flox:Cre+ (RalAB DKO) and RalAflox/flox:RalBflox/flox:Cre- (RalAB WT). 8-
24 week age and sex matched mice were used in all experiments, with data from male 
and female mice analysed and presented together. The local ethics committee at the 
University of Bristol, UK, approved all animal studies and mice were bred for this 
purpose under the UK Home Office project license PPL30/2908. 
 
Human and mouse platelet preparation – Human blood was obtained from healthy 
volunteers in accordance with the local research ethics committee at the University of 
Bristol (LREC number E5736). Animals were sacrificed by CO2 asphyxiation and blood 
was drawn from the inferior (caudal) vena cava as previously described21. Platelets 
were prepared as previously described22 and rested for 30 min at 30°C in the presence 
of 10 μM indomethacin and 0.02 units/ml of apyrase prior to stimulation. For flow 
cytometry and releasate studies, washed mouse platelets were recalcified to a final 
concentration of 1 mM with CaCl2 1 minute prior to stimulation. 
 
Generation of GST fusion proteins – pGEX4T1-GST-RalBP1 and Ral mutant 
constructs were generated as previously described18. Ral mutants were PCR cloned 
into a pGEX4T1 vector before generation of GST-beads using standard techniques. 
Briefly, BL21(DE3)pLysS protease-negative bacteria from Agilent Technologies 
(Cheadle, UK) were transformed and grown to log phase in 500 mL of LB (lysogeny 
broth) media supplemented with 0.5 % glucose before induction with 0.2 mM IPTG 
(isopropyl β-D-1-thiogalactopyranoside) for 3 h at 30 oC. Bacteria were pelleted by 
centrifugation before resuspension in 15 mL of PBS lysis solution (1 x PBS, 1 mM DTT 
[Dithiothreitol], 1 x complete protease tablet/50 mL, 0.1 % Triton-X) and sonicated. 
Bacterial lysate was then centrifuged at 27,000 g and supernatant collected, before 
incubation with GST beads for 1 hr on a roller. 
 
Pulldown assays – 300 μl of human platelets at 4 x 108 platelets/ml were stimulated 
with indicated agonists before lysis with 2x NP40 buffer (20 % glycerol, 2 % NP40, 400 
mM NaCl, 50 mM HEPES, 5 mM MgCl2, 2 μM microcystin-LR, 1 x complete mini EDTA-
free protease inhibitor tablet/5 mL). Lysates were placed on ice for 10 min with 30 μl 
removed and added to 4 x LDS sample buffer supplemented with 50 mM DTT to be 
used as a loading control. Remaining lysate was clarified by centrifugation before 
rotation for 1 h at 4 oC with 25 μl of GST-bead slurry. Beads were washed with ice-cold 
1 x NP40 buffer three times before addition of 20 μl 2 x LDS sample buffer with DTT. 
Input and pull-down samples were incubated at 80 oC for 10 min before analysis by 
immunoblotting. 
 
Electrophoresis and immunoblotting - Appropriate percentage tris-glycine SDS 
(sodium dodecyl sulphate)-polyacrylamide gels were used to run platelet proteins. Gels 
were then transferred onto either Immobilon P or FL depending on the developer in use 
(P for an ECL system, FL for a fluorescence system). Membranes were blocked for an 
hour at RT in 5 % BSA (bovine serum albumin) before subsequent incubation with 
primary and secondary antibodies between several wash stages. Proteins were either 
detected using an ECL and film detection system or a fluorescence based Li-Cor 
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Odyssey CLx (Lincoln, USA). 
 
Quantification of integrin αIIbβ3 activation and P-selectin expression – Flow 
cytometry analysis of platelets was performed as previously described23. Samples were 
analysed on a BD Biosciences FACScan flow cytometer, with raw data exported and 
analysed using Flowing Software. 
 
Quantification of PF4 and TGF-β secretion – Washed mouse platelets at 2 x 108 
platelets/mL were stimulated with indicated concentrations of agonist for designated 
time periods at 37 oC, before centrifugation at 650 g for 1 min to isolate releasate. 
Control total samples were generated by lysing unstimulated platelets with an equal 
volume of 1 % Triton-X before 3 cycles of snap freezing. For PF4 studies releasate and 
total samples were diluted 1/250 and 1/500 in reagent diluent (0.5 % BSA, 0.05 % 
TWEEN in PBS). In TGF-β studies releasate and total samples were diluted 1/20 and 
1/40 respectively. Determination of PF4 and TGF-β levels were achieved with the use of 
appropriate kits, where concentration of analytes was achieved with the generation of a 
standard curve. All kits were used according to the manufacturer’s protocol, with 
colorimetric readout at 450/540nm achieved with the use of a TECAN Infinite 200 PRO 
microplate reader (Reading, UK). 
 
Antibody microarray analysis of platelet releasate – 800 μl aliquots of mouse 
platelets at 4 x 108 platelets/mL were stimulated with 3 μg/mL CRP-XL for 10 min at 37 
oC, before centrifugation at 650 g for 10 min to isolate releasate. 700 μl of releasate was 
supplemented with 300 μl Array Buffer 6 and 500 μl Array Buffer 4 before completion of 
the assay according to manufacturer’s instruction. Proteins were detected with an ECL 
and film system before quantification with ImageJ. 
 
Immunofluorescence – Platelets were prepared as previously described with minor 
modifications24. Mouse PRP was fixed with 4 % PFA and 1 % BSA in PBS for 15 min 
before being spotted onto coverslips. Platelets were incubated in 100 % humidity at 37 
oC for 90 min before rinsing with PBS and permeabilisation with 0.2 % Triton-X. 
Platelets were blocked with 0.2 % BSA for 30 min before immunostaining with 
designated antibodies or IgG controls overnight, with unstained and secondary-only 
samples also used as controls. Coverslips were mounted before images were acquired 
with a Leica SP5-AOBS confocal laser scanning microscope attached to a Leica SM 
I6000 inverted epifluorescence microscope. Deconvolution of images and post 
processing was achieved with the use of Huygens Professional and Volocity. 
 
In vitro thrombus formation – Quantification of thrombus formation on collagen under 
flow was performed as previously described25. Briefly, IBIDI μ-Slide VI0.1 chips were 
coated with 50 μg/mL collagen for 2 hr before being flushed and blocked with 2 % fatty 
acid free (FAF) BSA prepared in HEPES Tyrode’s buffer. Mouse blood was taken as 
above and anticoagulated with 2000 U/ml heparin and 20 μM PPACK (1:9 v/v) before 
loading with 2 μM DiOC6. Blood was then transferred to a 1 mL syringe and perfused 
using an Aladdin AL-1000 syringe pump (World precision instruments, UK) at a shear 
rate of 1000 s-1 for 2 min. Platelets were fixed by perfusion of 4 % PFA through 
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channels for 4 min before non-adherent cells were flushed away with HEPES Tyrode’s 
buffer. IBIDI mounting medium was used to preserve fixed platelets for imaging. 
Thrombus formation was examined by generating confocal z-stacks (1024 x 1024 
pixels, 0.5 μm stack distance) from 5 randomly chosen fields of view using a Leica SP5-
II confocal laser scanning microscope attached to a Leica DMI 6000 inverted 
epifluorescence microscope (Leica Microsystems, UK). 
 
Quantification of platelet aggregation and δ-granule secretion - Aggregometry and 
dense granule secretion assays were completed as previously described22. Aggregation 
results were expressed as “% Max Aggregation” and δ-granule secretion as “Peak ATP 
release in nM”. 
 
In vivo thrombus formation – Quantification of in vivo thrombus formation was 
performed as previously described26. Briefly, mice were anesthetized with 100 mg/kg 
ketamine and 10 mg/kg xylazine before labelling of platelets by intravenous 
administration of 100 mg/kg DyLight 488-conjugated anti-GPIbβ antibody (mice 
weighing over 30g were excluded from experiments). Carotid arteries were exposed 
before 15 % FeCl3-soaked filter paper was placed on the arterial adventitia for 3 min. An 
Olympus BX51WI fixed stage microscope was used to acquire a time-lapse of the injury 
site for 20 min, with post processing of images completed with ImageJ. Background 
florescence values measured upstream of the injury site were subtracted from 
thrombus-specific fluorescence, and data are expressed as integrated density values. 
 
Quantification of platelet-leukocyte aggregate formation – Mouse whole blood was 
anticoagulated with 4 % trisodium citrate and 2000 U/ml Heparin (1:10 v/v) before 
incubation with RBC lysis buffer (1:5.5 v/v) and agitated for 15 min before centrifugation 
at 500 g for 5 min. Half the volume of supernatant was aspirated and replaced with RBC 
lysis buffer before further agitation (10 min) and centrifugation. The formed pellet was 
resuspended in modified HEPES-Tyrode’s solution to double the initial volume of whole 
blood, before stimulation with indicated concentrations of CRP-XL for 10 min. Samples 
were stained with 0.5 μg PE-CD45 and FITC-CD41 antibodies for 5 min before 
quenching by addition of HEPES-Tyrode’s buffer (1:9 v/v). Samples were analysed by 
flow cytometry using a BD Biosciences Accuri C6 Sampler plus. Leukocyte populations 
were identified according to forward and side scatter profiles. Positive PE and FITC 
events within the leukocyte region signified platelet-leukocyte aggregates, with 
appropriate IgG antibody controls used to determine false positive results. Results are 
expressed as the median FITC signal present in the Pl-Leuk gate. 
 
DSS-induced ulcerative colitis model – 10 8-10 week old RalAB WT and DKO mice 
littermate pairs were subject to a week of acclimatisation before their drinking water was 
replaced with a 5 % DSS solution. Over a 10-day period mice were given ad libitum 
access to the DSS solution while being monitored for clinical signs of colitis including 
bodyweight loss, loose stools and presence of occult or gross blood in stools. Clinical 
observations were given scores based on severity and subsequently graphed. 
 
Transmission electron microscopy - Subcellular mouse platelet morphology was 
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analysed by transmission electron microscopy. Ultrathin counterstained sections were 
prepared as previously described27. ImageJ was then used to count dense and alpha 
granules in equivalent-sized fields of view. 
 
Lysosomal secretion - Lysosomal secretion was determined using a β-
hexosaminidase assay. Mouse platelets at 2 x 108 platelets/ml were stimulated with 
indicated concentrations of agonist for 10 min at 37 oC. Samples were then centrifuged 
at 650 g for 1 min to isolate releasates. Control total samples were generated by lysing 
unstimulated platelets with an equal volume of 1 % Triton-X before 3 cycles of snap 
freezing. 20 μl of releasate/control was then incubated with 20 μl of 5 mM P-NAG (4-
Nitrophenyl N-acetyl-β-D-glucosaminide) made up in citrate phosphate buffer (80 mM 
Na2HPO4, 60 mM citric acid, pH 4.2) for 2 hr at 37 oC. Reactions were quenched with 
the addition of 200 μl of 0.1 M NaOH before reading of absorbance at 405 nm in an 
Opysys MR platereader made by Dynex Tehnologies (Worthing, UK) 
 
Statistical analysis – All statistical analysis was performed with GraphPad Prism 5.03. 
All data are representative of >3 experiments, represented by mean ± standard error of 
the mean (exact number of repeats are detailed in figure legends). Antibody microarray 
data was n=2, with no statistical test performed (Supplementary Figure I). Normality 
testing was conducted with the use of a Kolmogorov-Smirnov test and supported by 
graphical inspection of data. T-tests and two-way ANOVA statistical tests were utilised 
where appropriate, with Bonferroni’s post-hoc test used for two-way ANOVAs.  
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Results  
 
Ral GTPases bind the exocyst upon platelet stimulation 
Immunoblotting confirmed expression of the Ral GTPases in both human and murine 
platelets28, with appropriate Ral deletion achieved in all gene-targeted Ral mouse lines 
(Figure 1A). Exocyst expression was confirmed by immunoblotting for components of 
the complex in platelet lysates alongside positive control lysates (Figure 1B)29-31. The 
data demonstrate the expression of the exocyst complex in both human and mouse 
platelets, supporting published platelet transcriptome studies32. 
 
Using a RalBP1-GST pulldown approach we showed that both RalA/B became 
maximally activated after 1 minute of stimulation with CRP-XL in human platelets 
(Figure 1C) – in line with previous findings18. Furthermore, we were able to show that 
Ral GTPases are activated by a panel of platelet agonists including ADP, U46619, CRP 
and PAR4-AP (Figure 1D). 
 
To determine if activated Ral GTPases associate with the exocyst complex in platelets, 
constitutively active mutant forms of RalA (Q75L), RalB (Q72L) and their inactive 
counterparts (S31N and S28N)1 were GST-tagged and used in a pulldown assay. Active 
forms of both RalA/B associated with Sec8/EXOC4 in basal and CRP stimulated 
conditions (Figure 1E), whereas there was no association of the exocyst with the 
inactive Ral mutants. 
 
The presence of at least one Ral GTPase is essential for P-selectin expression on 
the surface membrane of mouse platelets 
Flow cytometry was used to simultaneously measure P-selectin expression and integrin 
αIIbβ3 activation in mouse platelets. Stimulation of RalA-/- platelets with CRP-XL showed 
no difference between WT and KO (Figure 2A, D), whereas RalB-/- platelets showed a 
~50 % reduction in P-selectin expression when stimulated with 10 μg/ml CRP-XL (p < 
0.01), with no alteration to integrin αIIbβ3 activation (Figure 2B, E). Analysis of RalAB 
DKO platelets in these assays showed a ~85 % reduction in P-selectin expression at 3 
(p < 0.05), 10 (p < 0.001) and 30 μg/ml CRP-XL (p < 0.001), with no change in integrin 
αIIbβ3 activation (Figure 2C, F). 
 
Experiments were repeated with PAR4-AP to determine the agonist specificity of the 
effects seen for CRP-XL (Figure 2G, H), with DKO platelets showing a ~60 % reduction 
when compared with WT counterparts (p < 0.001). Samples were also prepared with the 
P2Y12 blocker AR-C66096 (ARC, 10 μM) and stimulated with PAR4-AP to rule out any 
δ-granule secretion defects contributing to the defect in α-granule secretion, as 
previously described33. However, in the presence of ARC, the reduction in P-selectin 
expression in RalAB DKO mice is preserved, suggesting no contribution from δ-granule 
secretion. Importantly, integrin αIIbβ3 activation was not altered in response to PAR4-AP. 
 
Ral deletion marginally alters α-granule cargo levels and release 
The substantial reduction in stimulated P-selectin expression in RalAB DKO platelets 
suggested a major defect in α-granule secretion, so it was important to quantify α-
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granule content and release in the RalAB WT and DKO platelets. PF4 and TGF-β 
release in response to platelet stimulation was assessed by ELISA (Figure 3A & B). The 
data however indicated no change in PF4 release, with only a small reduction in TGF-β 
release observed in response to 125 μM PAR4-AP (p < 0.05) – suggesting largely 
unaltered α-granule content release in DKO platelets. These data were further 
supported by the use of an antibody microarray to assess the effect of Ral deletion on a 
wider range of α-granule cargo, where relative levels of angiogenesis-associated 
polypeptides were determined in supernatants isolated from WT and DKO platelets 
stimulated with 3 μg/ml CRP-XL. Calculated DKO:WT ratios of the most abundant 
proteins present in samples from two separate assays showed no change in levels of 
released polypeptides between WT and DKO (Supplementary Figure I). Furthermore, 
lysosomal secretion as determined by measurement of released β-hexosaminidase was 
also unaltered in DKO platelets (Supplementary Figure II). 
 
Due to the observed P-selectin defect, it was important to assess if P-selectin 
localisation was altered upon Ral deletion, which we determined by 
immunofluorescence microscopy (Figure 3C). Acquired images show P-selectin staining 
in the RalAB DKO is comparable to WT platelets, localising to granular compartments 
within the platelet. 
 
Although the localisation of P-selectin was unaltered, it was also important to investigate 
expression levels of α-granule proteins within the RalAB WT and DKO platelets. 
Immunoblotting showed that P-selectin expression, normalised to loading control 
GAPDH, was marginally greater in RalAB DKO platelets compared to WT (p < 0.05, 
Figure 3D). Quantification of α-granule cargo content by ELISA showed no change in 
PF4 levels, but a marginally elevated level of TGF-β present within RalAB DKO platelets 
(p < 0.05, Figure 3D). Furthermore, TEM images of RalAB WT and DKO platelets 
showed no overt difference in morphology or granule numbers (Supplementary Figure 
IIIA, B). Taken together, these results indicate that Ral deletion does not cause major 
alterations in granule biogenesis or cargo loading. 
 
Comparing kinetics of α-granule secretion highlights a major role for Ral 
GTPases in P-selectin surface expression 
To gain further insight into the α-granule release reaction occurring in RalAB WT and 
DKO platelets we monitored levels of P-selectin surface expression, integrin αIIbβ3 
activation, PF4 release and TGF-β release in response to stimulation with 3 µg/ml CRP-
XL at pre-defined time points (Figure 4A, B, D, E). In addition, total platelet P-selectin 
levels upon stimulation were determined by western blotting to address whether P-
selectin was lost in response to stimulation in transgenic mice (Figure 4C). 
 
As determined by flow cytometry, we see an increasing difference in P-selectin surface 
exposure between the RalAB WT and DKO samples over time (p < 0.001), with a ~90 
% reduction in P-selectin surface exposure observed in the RalAB DKO samples by 30 
mins (Figure 4A). Measured simultaneously, we observed no change in integrin αIIbβ3 
activation at the same time points (Figure 4B). These data are further supported by real-
time monitoring of P-selectin exposure and integrin αIIbβ3 activation, again showing a 
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marked reduction in P-selectin exposure over 15 min in RalAB DKO platelets, but no 
change in integrin αIIbβ3 activation (Supplementary Figure IVA, B). Additionally, Ral 
deletion did not lead to an alteration in total P-selectin levels upon stimulation with 3 
µg/ml CRP-XL or 125 µM PAR4-AP (Figure 4C). 
 
Finally, measurement of PF4 and TGF-β release by ELISA over the same time points in 
response to 3 µg/ml CRP-XL highlighted no significant difference between RalAB WT 
and DKO (Figure 4D, E). Combined with data from Figure 3, these results indicate no 
major differences in soluble cargo release profiles of RalAB WT and DKO platelets, but 
a severe defect in P-selectin surface expression. 
 
Ral deletion reduces δ-granule secretion in response to sub-maximal platelet 
stimuli, but does not affect aggregation or thrombus formation  
Lumi-aggregometry was used to measure δ-granule secretion and platelet aggregation 
in response to platelet stimulation (Figure 5A, B). Deletion of RalA or RalB alone had no 
effect on δ-granule secretion or aggregation (Supplementary Figure V). RalAB DKO 
mice showed a small reduction in δ-granule secretion in response to 0.6 μg/ml CRP (p < 
0.01) and 125 μM PAR-4 AP (p < 0.05), but this did not translate to a significant 
reduction in measured platelet aggregation. 
 
Similarly, deletion of RalA or RalB did not alter thrombus formation in vitro 
(Supplementary Figure VI) and although thrombus volume and surface area were 
marginally reduced in the RalAB DKO platelets, this was not found to be significant 
(Figure 5C-E). Measurement of in vivo thrombus formation in a ferric chloride injury 
model again showed no change in the rate or extent of thrombus formation (Figure 5F-
H). Furthermore, it is important to note that platelet Ral deletion has no effect on whole 
blood haematology values or platelet surface expression of CD41, GPVI, GPIb and 
integrin α2 (Supplementary Figure IIIC, D), which could mask any alterations in 
aggregation and thrombus formation. 
 
Platelet-leukocyte interactions are reduced in RalAB DKO mice when compared 
with WT 
Platelet P-selectin is required for the initial tethering of activated platelets to leukocytes 
and endothelial cells34,35. This tethering allows leukocytes to be recruited to inflamed 
tissue through extravasation, which contributes to the development of pathologies such 
as inflammatory bowel disease (IBD) and rheumatoid arthritis36,37. As platelet Rals 
regulate stimulated P-selectin expression on the platelet membrane, it was possible that 
platelet-leukocyte interaction was disrupted for RalAB DKO platelets. 
 
To determine if these interactions were altered, we measured platelet-leukocyte 
aggregate formation in response to platelet stimulation by CRP-XL (Figure 5). Whole 
blood from RalAB WT and DKO mice was subjected to RBC lysis before incubation with 
increasing concentrations of CRP-XL. Leukocytes and platelets were stained with 
CD45-PE and CD41-FITC before quenching of the reaction and subsequent analysis by 
flow cytometry. Appropriate IgG control samples were used to prevent measurement of 
false-positive events, allowing for generation of quadrant plots where single events 
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positive for both platelets (FITC) and leukocytes (PE) would be present in the top right 
quadrant – within the Pl-Leuk gate (Figure 5B). In Figure 5C, representative data from 
basal and CRP-stimulated WT/DKO mouse lines illustrates a reduced shift in FITC 
signal within the Pl-Leuk gate in the DKO sample upon stimulation, signifying platelets 
bound to leukocytes. Measurement of “Median FITC within Pl-Leuk” in all samples 
showed a ~70 % reduction in platelet-leukocyte interaction in the DKO mouse line, 
when compared with WT (p < 0.001), signifying fewer platelets bound to individual 
leukocytes in RalAB DKO samples (Figure 5D). Overall these results suggest that 
platelet Rals are critical for mediating this response, and may indicate a major role for 
these GTPases in inflammatory processes. 
 
To further explore the role platelet Rals play in leukocyte extravasation and 
inflammatory conditions in vivo, RalAB WT and DKO mice were subject to a DSS-
induced model of ulcerative colitis, where drinking water was replaced with 5 % DSS 
over a 10 day period as previously described38,39. The DSS model was chosen in 
particular due to previous studies highlighting the model’s sensitivity to the presence of 
platelet mediated leukocyte extravasation, as well as P-selectin function40-42. 
 
Mice were monitored for symptoms associated with DSS-induced ulcerative colitis 
including bodyweight loss, stool consistency and presence of blood in stools, with 
scores generated based on severity (Supplementary Figure VIIA, B). An overall clinical 
score was generated by the addition of bodyweight and stool scores which was used as 
a measure of the progression of the DSS-induced ulcerative colitis model 
(Supplementary Figure VIIC). Results show a significant decrease in all measured 
parameters on day 4 of the study, with stool scores also significantly reduced on day 2. 
Taken together, these results suggest that at early stages of DSS-induced ulcerative 
colitis, platelet Ral deletion reduces the symptoms associated with the progression of 
the pathology. Although the study was carried out for 10 days, by day 8 over half the 
RalAB WT mice had to be culled due to reaching humane endpoints and for that reason 
data from the rest of the study is not shown. Upon termination, colons were dissected 
from mice and measured lengthways as a metric of gross pathology – revealing no 
significant alteration in terminal pathology (data not shown). 
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Discussion 
 
Ral GTPases are important drivers of cell proliferation and metastasis in multiple human 
cancers, and as such are key targets for development of novel anti-cancer therapies. In 
addition, they have been shown to regulate cell adhesion and membrane trafficking 
including exocytosis, and so it was important to determine their contribution to platelet 
function. Here we showed that the two genes had overlapping and largely mutually 
redundant roles in regulating P-selectin externalisation, suggesting a role in regulating 
α-granule secretion. Surprisingly however dual Ral deletion had no overt effect upon 
release of α-granule content, whilst substantially blocking P-selectin surface expression. 
This has implications for the effects of Ral blockade on platelet function, which may 
specifically abrogate platelet-leukocyte interaction and subsequent inflammatory 
responses, without significantly affecting platelet function in thrombosis. This would 
allow the development of targeted therapies for diseases of platelet-mediated 
inflammation. 
 
In the present study we showed the expression of RalA and RalB in both human and 
mouse platelets, generating the first genetically modified mouse lines with platelet-
specific deletion of RalA, RalB and both together (Figure 1A). Previously published work 
showed that both RalA/B became maximally activated 1 min after platelet stimulation 
and were activated by numerous platelet agonists18, and our data in Figure 1C&D are 
consistent with these findings. As one of the main effectors of Rals is the exocyst 
complex4,5,43, we used GST-bound constitutively active and inactive forms of Ral 
GTPases to pull down interactors, and were able to confirm that active Ral GTPases 
bind the exocyst complex upon activation (Figure 1E). It is therefore likely that Rals 
mediate their activity in platelets through activation of the exocyst complex.  
 
Quantification of P-selectin expression by flow cytometry revealed significant defects in 
both RalB KO and RalAB DKO platelets, suggesting Ral GTPases play key roles in α-
granule secretion (Figure 2). The results also imply a degree of functional redundancy 
between the two GTPases, as the reduction in α-granule secretion observed in the 
RalAB DKO (~85 %) was greater than the sum of reduction in both RalA KO (0 %) and 
RalB KO (~50 %) mouse lines. Data also indicate that RalB is the dominant isoform of 
Ral GTPases regulating α-granule secretion, with RalA only playing a minor role. 
Further investigation into RalAB DKO α-granule secretion showed that this defect in 
secretion was not specific to GPVI agonists, with platelet stimulation by the PAR4-AP 
revealing a ~60 % reduction in P-selectin externalization – suggesting RalAB DKO 
platelets can sustain a moderate level of P-selectin surface expression when stimulated 
with high levels of a potent platelet agonist. As defects in δ-granule secretion are known 
to contribute to α-granule secretory defects33, the P2Y12 blocker ARC was used to 
block any platelet activation by ADP released from δ-granules. Again, the defect 
observed without ARC was preserved, with a major reduction observed in the RalAB 
DKO mouse line. Integrin αIIbβ3 activation was not altered in any of these assays, 
implying that the P-selectin surface expression defect cannot be attributed to a defect in 
platelet activation or integrin signalling. Taken together with previous studies19,44 the 
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data indicate that the α-granule secretory defects observed are likely to be due to 
diminished Ral-exocyst interaction. 
 
While P-selectin surface expression was reduced, it was important to assess the 
release of non-membrane bound, soluble α-granule cargoes to gain a full understanding 
of the secretory defect. Interestingly, quantification of TGF-β and PF4 secretion from 
DKO platelets was largely unchanged from WT, with only TGF-β release in response to 
125 µM PAR4-AP being significantly reduced by ~20 %, suggesting broadly normal 
cargo release (Figure 3A, B). Antibody microarray analysis of releasates isolated from 
stimulated WT and DKO platelets supported this, showing no alteration in the release of 
other known α-granule cargoes such as angiopoietin-1, endostatin, platelet derived 
growth factor, stromal cell-derived factor 1, thrombospondin-2, VEGF10,45 
(Supplementary Figure I). Additionally, we investigated the localisation of P-selectin in 
WT and DKO platelets by immunofluorescence microscopy (Figure 3C). Acquired 
images show similar P-selectin patterning in both WT and DKO, with P-selectin 
appearing to be localised to granular compartments within the platelet. Acquired TEM 
images of the WT and DKO platelets revealed no alteration in morphology or granule 
count (Supplementary Figure IIIA, B) - implying no role for Rals in controlling platelet 
morphology. 
 
It was important to rule out any roles for Rals in granule biogenesis or cargo loading. 
Determination of relative P-selectin levels in platelet lysates by immunoblotting showed 
a small increase in RalAB DKO platelets compared to WT (Figure 3D). Measurement of 
total PF4 content by ELISA showed no difference between WT and DKO platelets, 
whereas TGF-β levels were slightly elevated. The data suggest that Ral GTPases play 
no role in platelet granule biogenesis or cargo expression. 
 
To further investigate the α-granule secretory events occurring in RalAB DKO platelets 
we monitored P-selectin surface expression, integrin αIIbβ3 activation, PF4 release and 
TGF-β release over time in response to CRP-XL stimulation (Figure 4). Results 
revealed a substantial reduction in P-selectin surface expression over 30 minutes in 
RalAB DKO platelets when compared with WT (Figure 4A, Supplementary Figure IVA). 
Conversely, simultaneous measurement of integrin αIIbβ3 activation showed no 
difference between mouse genotypes (Figure 4B, Supplementary Figure IVB). 
Examining the P-selectin data shows a small increase over time in DKO P-selectin 
surface expression – suggesting some antibody binding to platelet P-selectin does 
occur upon stimulation. It is however not possible to deduce whether this antibody 
binding occurs upon a transient fusion event of the α-granule, where α-granule P-
selectin is briefly exposed to the external milieu or if a low level of P-selectin surface 
expression takes place. Additionally, we observed no early appearance or spiking of the 
P-selectin signal in the DKO platelets in our kinetic studies (Figure 4A, Supplementary 
Figure IVA), which could have otherwise suggested an increased rate of P-selectin 
shedding or clearance. Supporting this observation, assessment of total platelet P-
selectin levels after stimulation with either CRP-XL or PAR4-AP showed no reduction in 
P-selectin levels in WT or DKO samples (Figure 4C). This data again suggests that Ral 
deletion does not increase P-selectin shedding from the surface membrane, and P-
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selectin is retained within/on the platelet membrane upon stimulation in both mouse 
lines. Finally, both PF4 and TGF-β release over 30 mins were not significantly altered 
by Ral deletion. Interestingly, there seems to be a disparity in the release kinetics of 
these two α-granule cargoes, with PF4 release peaking at 10 minutes, earlier than TGF-
β release. This could be explained by PF4 being sequestered back into the platelets at 
a faster rate than TGF-β, or that PF4 was broken down faster than TGF-β after release. 
There is also the possibility of differential α-granule secretion causing a faster release of 
PF4 compared to TGF-β, through release from distinct subsets of α-granules17,46. 
 
Taken together, the absence of Ral GTPases causes an α-granule secretory defect 
where soluble cargoes are released, but P-selectin is not substantially expressed on the 
surface membrane. We believe there are two plausible explanations for these 
observations; (i) Rals may regulate differential secretion of α-granules with differential 
P-selectin content or (ii) Rals regulate kiss-and-run exocytosis where fusion of granule 
with target membrane is transient. Differential α-granule secretion, as described 
previously17,46, could cause the secretion of different sub-populations of α-granules 
lacking or possessing P-selectin on their membranes. There is already evidence to 
suggest that P-selectin is differentially packaged from vWf in mouse platelets, indicating 
the presence of distinct subpopulations of P-selectin positive and negative α-granules47. 
The deletion of Ral GTPases, which localise to secretory granules4, could therefore 
result in diminished secretion of P-selectin positive α-granules, but not P-selectin 
negative granules containing the released peptides we detected (Figure 2, 
Supplementary Figure I). Alternatively, the phenomenon could reflect kiss-and-run 
exocytosis, where a full fusion event of the secretory granule does not occur – this has 
previously been shown in platelets using single-cell amperometry48,49. Not dissimilar to 
chromaffin cells50, platelet kiss-and-run exocytosis may occur upon cell stimulation and 
be the favoured fusion event in the absence of Ral GTPases. In this way, transient 
reversible fusion of α-granules with the plasma membrane may occur, but full 
irreversible fusion does not. This would allow for soluble cargo to be released, but α-
granule membrane incorporation into the surface membrane would not occur. In a 
similar vein, it also plausible that Ral GTPases play a role in the docking of α-granules, 
comparable to a suggested role for calpain in platelets51. 
 
Measurement of δ-granule secretion and aggregation showed no significant difference 
in single Ral knockout mouse lines (Supplementary Figure V). RalAB DKO platelets did 
however show a small reduction in δ-granule secretion in response to sub-maximal 
concentrations of CRP-XL and PAR4-AP (Figure 5A), similar to the observed defect in 
TGF-β secretion (Figure 3B). It should also be considered that this δ-granule secretory 
phenotype may alter α-granule release as previously shown33, which could explain the 
observed reduction in TGF-β release. Overall, our findings suggest Ral GTPases play a 
limited role in the regulation of δ-granule secretion, contrary to a previous study which 
showed that interruption of Ral-exocyst interactions in permeabilised human platelets 
reduced δ-granule secretion by ~70 %19. The difference with our study may result from 
the very different technical approaches used. It is also possible however that there are 
species differences between human and mouse platelets. The previous study does 
however indicate that Ral GTPases increase the sensitivity of δ-granule secretion in 
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response to low level platelet stimuli, which is consistent with our data, and may be 
mediated by a calcium-sensing role for Ral GTPases.  
 
While the observed P-selectin and δ-granule secretory defects did not translate into 
reduced aggregation or thrombus formation responses (Figure 5), it is interesting to 
note that previous studies have implied a role for P-selectin in thrombus formation52-54. 
This may be due to a difference in models used in previous studies, where P-selectin-/- 
mice or P-selectin blocking antibodies have been used to halt P-selectin function. As the 
RalAB DKO mice here are generated as platelet-specific using a floxed conditional 
allele, endothelial cell function and endothelial P-selectin expression55 are not disrupted 
– in contrast to P-selectin-/- mice or when using blocking antibodies. We show RalAB 
DKO platelets also express small amounts of surface P-selectin when stimulated with 
high concentrations of potent agonist (Figure 2G), suggesting P-selectin function is not 
completely ablated in our mice. In addition, since the major drivers of platelet 
aggregation and thrombus formation (integrin αIIbβ3 activation and δ-granule 
secretion56,57) are largely unaltered in the RalAB DKO mice, this may also help explain 
why arterial thrombus formation is normal in these mice. 
 
It was important to explore the effect of reduced surface P-selectin expression on 
platelet-leukocyte binding (Figure 6). RalAB DKO samples showed a ~70 % reduction in 
the platelet-leukocyte interactions, as a result of reduced P-selectin exposure58,59. 
These results strongly indicate roles for platelet Ral GTPases in inflammatory 
responses, so we chose to investigate platelet Ral deletion in vivo using a DSS-induced 
ulcerative colitis model, due to evidence directly linking platelet α-granule secretion to 
IBD and Crohn’s disease60-62. Clinical observations associated with symptoms of DSS-
induced ulcerative colitis including weight loss, stool consistency/diarrhoea and 
presence of blood in stools were significantly reduced in RalAB DKO mice in early 
stages of the study (Supplementary Figure VII). This is likely to be due to reduced 
platelet-leukocyte interactions in the RalAB DKO mice and a subsequently slowed rate 
of leukocyte extravasation. Although by day 6 of the study there was no significant 
difference in clinical scores between RalAB WT and DKO, results from days 2 and 4 
point to a role for platelet Rals in the early stages of the inflammatory process in this 
model. While there is evidence to suggest that the PF4 promoter model used in this 
study could lead to Cre expression in cells in the distal colon63, the proportion of cells 
expressing Cre is not determined. With this in mind we performed an additional control 
experiment comparing platelet-leukocyte interactions in Cre expressing and non-
expressing mice, with results showing that the presence of the Cre-PF4 promoter does 
not alter platelet-leukocyte interactions (Supplementary Figure VIII). It would however 
be ideal to include in this study mice in which Cre was selectively expressed in colon 
epithelial cells, but in the absence of a clean promoter system for such a study, we 
cannot convincingly assign phenotype solely to platelet-specific deletion of Rals. The 
results do however highlight the possibility that platelet-expressed Ral GTPases could 
be targets for the treatment of disorders associated with platelet-leukocyte interaction. 
Finally, these results also raise questions regarding the use of Ral inhibitors in the 
treatment of cancer2, and would need further investigation if the use of these drugs 
significantly altered platelet or leukocyte function.  
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In conclusion, we have identified that platelet Ral GTPases are key regulators of P-
selectin surface expression, playing only a minor role in regulating the release of soluble 
platelet cargoes. We propose two potential mechanisms: differential secretion of P-
selectin positive α-granule subsets or kiss-and-run exocytosis. The resultant major 
defect in platelet P-selectin expression in the absence of RalAB induces a marked 
defect in platelet-leukocyte interaction. Pf4-Cre+ RalA/Bflox mice showed reduced 
symptoms in early stages of inflammatory bowel disease, in a mouse model system. 
Platelet Ral GTPases could therefore form a novel target for modulating inflammatory 
disease in conditions where platelet P-selectin surface expression plays an important 
role.  
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Highlights: 
• Genetic deletion of RalA and RalB GTPases in mouse platelets highlights a major 
role for Rals in regulating the surface expression of α-granule P-selectin, but not in 
the release of soluble α-granule cargo. 
• Diminished P-selectin surface expression leads to a reduction in the formation of 
platelet-leukocyte interactions in vitro. In an in vivo mouse model of inflammatory 
bowel disease (DSS-induced ulcerative colitis) onset of the pathology is delayed in 
Pf4-Cre+ RalA/Bflox mice. 
• Ral GTPases could be important novel targets for the selective control of platelet-
mediated immune cell recruitment and inflammatory disease. 
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Figure 1. Ral GTPases and the exocyst complex in platelets. (A) Platelet lysates (4 x 108 
platelets/mL) from human and mouse (wild type (WT) or genetically modified as indicated) were 
probed for the presence of RalA and RalB GTPases. (B) Control cell lysates from PC-12, NRK 
and RPE-1 (2.5 mg/ml) were probed for exocyst components Sec5, Sec6 and Sec8 alongside 
human and murine platelet lysates (4 x 108 platelets/mL). (C) Human platelets were isolated and 
stimulated with 1.5 μg/mL CRP-XL for the times indicated. RalBP1-GST bead pull-downs, to 
recover active (GTP-bound) Rals, were blotted for RalA (RalA-GTP row) or RalB (RalB-GTP 
row). Input lysates were blotted for RalA and RalB, as loading controls, as shown. (D) Human 
platelets were isolated and stimulated for 1 min with agonists indicated, lysed and incubated 
with RalBP1-GST beads to precipitate active Rals. Pull-downs were blotted for RalA (RalA-GTP 
row) or RalB (RalB-GTP row). Input lysates were blotted for RalA and RalB, as loading controls, 
as shown. (E) Human platelets were isolated and stimulated with 3 μg/mL CRP-XL for 1 minute 
prior to lysis and incubation with constitutively active (Q75L, Q72L) or inactive (S31N, S28N) 
mutant forms of RalA/B-GST beads. Proteins were eluted and probed for the exocyst 
component Sec8. Data shown are representative of 3 independent experiments. 
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Figure 2. Ral GTPases regulate P-selectin expression on the surface membrane. Flow 
cytometry was used to determine P-selectin expression on the surface membrane (A-C, G) and 
integrin αIIbβ3 activation (D-F, H) in RalA WT/KO (A, D), RalB WT/KO (B, E) and RalAB 
WT/DKO (C, F, G, H). Mouse platelets (5 x 107 platelets/mL) were incubated with PE-
conjugated anti-integrin αIIbβ3 and FITC-conjugated anti-CD62P/P-selectin antibodies before 
stimulation with indicated concentrations of CRP-XL (A-F) and PAR4-AP. For some 
experiments, shown in G & H, platelets were pretreated with 10 μM ARC for 10 min. Data for A-
F are mean values ± SEM (n=7) and G, H are mean values ± SEM (n=4). Statistical analysis 
was performed by 2-way ANOVA with Bonferroni’s post-hoc test (*** = p < 0.001, ** = p < 0.01, * 
= p < 0.05). 
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Figure 3. Ral deletion marginally alters α-granule cargo levels and release. Secretion of 
PF4 (A) and TGF-β (B) from CRP-XL and PAR4-AP-stimulated RalAB WT and DKO platelets (2 
x 108 platelets/mL) was determined by ELISA and are displayed as a percentage release of total 
platelet content. Platelets were stimulated with indicated concentrations of agonist before 
releasates were isolated by centrifugation of samples at 650 g for 1 min. Data shown are mean 
± SEM (n=5), statistical analysis – 2-way ANOVA with Bonferroni’s post-hoc test (* = p <0.05). 
(C) Platelets were isolated from RalAB WT and DKO mice and fixed before spotting on 
coverslips and permeabilisation with 0.2 % Triton-X. Samples were immunostained with 
ActinGreen (yellow) and goat anti-mouse P-selectin and anti-goat Alexafluor 642 (magenta). 
Samples were visualised by confocal microscopy, with multiple z-stacks shown in extended 
focus. Images are representative of 3 separate experiments (n=3). Scale bar is equal to 1 μm. 
(D) Total P-selectin content relative to GAPDH in platelet lysates was determined by western 
blotting and densitometry. Total TGF-β and PF4 content was determined by ELISA. Bars 
represent mean ± SEM (n=3-5). Statistical analysis was performed by unpaired t-test (* = p < 
0.05).  
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Figure 4. Investigating the kinetics of α-granule secretion in RalAB WT and DKO 
platelets. Flow cytometry was used to determine P-selectin expression on the surface 
membrane (A) and integrin αIIbβ3 activation (B) in RalAB WT/DKO platelets over a 30 minutes 
period. Mouse platelets (5 x 107 platelets/ml) were incubated with PE-conjugated anti-integrin 
αIIbβ3 and FITC-conjugated anti-CD62P/P-selectin antibodies before stimulation with 3 µg/ml 
CRP-XL. Sample were then fixed with an equal volume of 2 % PFA after 0, 2, 5, 10 and 30 
minutesof stimulation. (C) Platelet P-selectin levels after stimulation were determined by 
western blotting. Platelets (4 x 108 platelets/ml) from RalAB WT and DKO mice were stimulated 
with 3 µg/ml CRP-XL or 125 µM PAR4-AP for 10 minutes before isolation by centrifugation. 
Supernatant was removed before pelleted platelets were resuspended and lysed. Platelet 
lysates were then probed for P-selectin, with GAPDH used as a loading control. Secretion of 
PF4 (D) and TGF-β (E) from RalAB WT and DKO platelets (2 x 108 platelets/mL) over 30 
minutes was determined by ELISA and are displayed as a percentage release of total platelet 
content. Platelets were stimulated with 3 µg/ml CRP-XL for 0, 2, 5, 10 and 30 minute before 
samples were centrifuged at 650 g for 1 min and releasates collected. Kinetic data (A, B, D, E)  
are mean ± SEM (n=5) with statistical analysis performed by 2-way ANOVA with Bonferroni’s 
post-hoc test (*** = p < 0.001). Blot image (C) is representative of 3 independent experiments 
(n=3). 
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Figure 5. Deletion of Ral GTPases does not alter aggregation or thrombus formation. ATP 
secretion (A) and max aggregation (B) were determined simultaneously by lumi-aggregometry. 
Mouse platelets (2 x 108 platelets/mL, from either RalAB WT or DKO mice were stimulated with 
indicated concentrations of CRP-XL, ADP, U44619 and PAR4-AP for 5 min with constant 
stirring. (C) Whole blood from RalAB WT and DKO mice was incubated with 2 μM DiOC6 before 
being flowed through a collagen-coated chamber (1000 s-1 for 2 min). Adherent platelets were 
fixed and representative images shown. Quantification of total thrombus volume (μm3) (D) and 
surface area covered (μm2) (E) is also shown. (F) A ferric chloride carotid injury model 
(described in Methods) was used to evaluate in vivo thrombus formation real-time in RalAB WT 
and DKO mice. Accumulation of fluorescently labelled platelets at the site of injury is shown by 
mean integrated fluorescence over 15 min (F), endpoint (at 15 min) integrated fluorescence (G) 
and area under curve (at 15 min, H). For (A, B) data are mean values ± SEM (n=4-7); statistical 
analysis – 2-way ANOVA with Bonferroni’s post-hoc test (** = p < 0.01, * = p < 0.05). For (C-E) 
data are mean values ± SEM (n=7); statistical analysis – unpaired t-test. For (F-H) data are 
mean values ± SEM (n=9); statistical analysis – unpaired t-test. Unpaired t-tests (D, E, G, H) 
found no significant difference between WT and DKO. 
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Figure 6. Platelet-leukocyte interactions are reduced in RalAB DKO mice compared with 
RalAB WT. Whole blood isolated from RalAB WT and DKO mice was subject to RBC lysis 
before stimulation with various concentrations of CRP-XL for 10 min. Samples were then 
stained with PE-conjugated anti-CD45 and FITC-conjugated anti-CD41. (A) Representative 
scatter plot showing platelet and leukocyte regions/gates post sample RBC lysis. (B) IgG 
antibody controls were used to generate quadrants determining specific antibody binding within 
the leukocytes gate. (C) FITC vs PE plots for basal and stimulated (10 μg/ml CRP-XL) WT/DKO 
samples within the leukocytes gate. Events detected within the top right quadrant signified 
events positive for both FITC (CD41) and PE (CD45) – indicating platelet-leukocyte (PI-Leuk) 
aggregates. (D) Median FITC fluorescence within the Pl-Leuk gate. For A-C, data shown are 
representative of 5 independent experiments. For D, data are mean values ± SEM (n=5). 
Statistical analysis was performed by 2-way ANOVA with Bonferroni’s post-hoc test (*** = p < 
0.001).  
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Supplementary Figure I. Ral deletion does not alter α-granule content release. Releasates 
from RalAB WT and DKO platelets stimulated with CRP-XL (3 μg/mL) were probed for 
angiogenesis-related proteins by antibody microarray. Bars represent relative protein abundance 
as a DKO:WT ratio; data are means from two separate pairs of mice (n=2).  
 
  
Supplementary Figure II. Ral deletion does not alter lysosomal secretion. RalA WT/KO (A), 
RalB WT/KO (B) and RalAB WT/DKO (C) platelets (2 x 108 platelets/ml) were stimulated with 
indicated concentrations of CRP-XL for 10 min before collection of releasates by centrifugation. 
Releasates were probed for β-hexosaminidase by incubation with P-NAG for 2 hours before 
quenching of the reaction with NaOH. Concentration of β-hexosaminidase was determined by 
colorimetric readout, with a lysed platelet control used as a total control. Data shown are mean ± 
SEM (n=3), statistical analysis was performed by 2-way ANOVA with Bonerroni’s post-hoc test, 
with no difference found between mouse lines.  
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Supplementary Figure III. Deletion of platelet Ral GTPases does not alter platelet count, 
receptor expression or morphology. Representative TEM images of RalAB WT and DKO 
platelets are shown (A) and quantified in (B). Numbers of platelet α- and δ-granules were 
evaluated from 3 pairs of mice, where granules were counted in 15 equivalent-sized fields of view. 
Statistical analysis by unpaired t-test showed no significant difference in granule numbers 
between WT and DKO. Bars represent mean values ± SEM (n=3). (C) Haematology values for 
whole blood isolated from RalAB WT and DKO mice. Data show mean, SEM, n values and 
statistical significance (p value) for differences between WT and DKO, for white blood cell count 
(WBC), red blood cell count (RBC), platelet count (PLT) and mean platelet volume (MPV) as 
indicated. (D) Surface expression of key platelet glycoproteins was determined by FACS on 
RalAB WT and DKO mouse platelets. Data are shown as % difference of DKO from WT values, 
with boxes representing mean values extending to 25th and 75th percentiles and whiskers 
representing max-min values (n=6). 2-way ANOVA with Bonferroni’s post-hoc showed no 
difference in glycoprotein surface expression between WT and DKO.  
RalAB WT RalAB DKO
Mean S.E. n Mean S.E. n p
WBC$count$(103/mm3) 7.60 0.80 15 8.92 0.94 15 ns
RBC$count$(106/mm3) 12.18 0.44 15 12.46 0.41 15 ns
PLT$count$(106/mm3) 1177.66 37.89 14 1204.87 47.94 14 ns
MPV$(μm3) 5.55 0.04 15 5.65 0.06 15 ns
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Supplementary Figure IV. Real-time determination of P-selectin surface expression and 
integrin αIIbβ3 activation in RalAB WT and DKO platelets. Flow cytometry was used to 
simultaneously visualise the kinetics of P-selectin expression on the surface membrane (A) and 
integrin αIIbβ3 activation (B) in RalAB WT and DKO platelets. Mouse platelets (2 x 106 
platelets/ml) were incubated with FITC-conjugated anti-CD62P/P-selectin and PE-conjugated 
anti-integrin αIIbβ3 and stimulated with indicated concentrations of agonist (final sample volume 
300 µl). Samples were immediately analysed by flow cytometry for 15 minutes at a flow rate of 
14 µl/min. Plots are representative of 3 separate mouse pairs (n=3). 
  
A
R
al
AB
W
T
R
al
AB
W
T
R
al
AB
(D
KO
R
al
AB
(D
KO
Basal 3 μg/mL(CRP5XL 125 μM PAR45AP Basal 3 μg/mL(CRP5XL 125 μM(PAR45AP
P5selectin(surface(expression Integrin(αIIbβ3 activationB
  
 
Supplementary Figure V. Individual RalA or RalB deletion does not alter δ-granule 
secretion or aggregation. ATP secretion and max aggregation in RalA WT/KO (A,C) and RalB 
WT/KO (B,D) platelets were determined simultaneously by lumi-aggregometry. Mouse platelets 
(2 x 108 platelets/mL) were stimulated with indicated concentrations of CRP-XL, ADP, U44619 
and PAR4-AP for 5 min with constant stirring. Data represent mean values ± SEM (n=4-7), 
statistical analysis – 2-way ANOVA with Bonferroni’s post-hoc test.  
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Supplementary Figure VI. Individual RalA or RalB deletion does not alter thrombus 
formation in vitro. Blood isolated from RalA WT/KO (A,B) and RalB WT/KO (C,D) mice was 
incubated with 2 μM DiOC6 before being flowed through a collagen-coated chamber (1000 s-1 for 
2 min). Adherent platelets were fixed and representative images shown. Quantification of total 
thrombus volume (μm3) and surface area covered (μm2) was achieved with Volocity image 
analysis software. Statistical analysis was performed by unpaired t-test, with no significant 
difference found between Ral WT and Ral KO mouse lines. 
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Supplementary Figure VII. Symptoms of DSS-induced ulcerative colitis are delayed in 
RalAB DKO mice when compared to WT. The drinking water of 10 RalAB WT and DKO age 
matched (8-10 week) pairs was replaced with 5 % DSS. Changes in mouse bodyweight were 
recorded, allowing for calculation of a bodyweight score (A) [0 % weight loss - 0, 1-5 % weight 
loss - 1, 5-10% - 2, 10-15 % - 3, >15 % - 4]. Stool scores (B) were generated by monitoring 
consistency and presence of blood in stools. Consistency of stools was ranked on a scale of 0-
4, with 0 being normal and 4 being diarrhoea. Likewise, presence of blood in stools was ranked 
on a scale of 0-4, with 0 being no blood and 4 being gross bleeding. The sum of consistency 
and blood presence scores represents the overall stool score (B). The overall clinical score (C) 
represents the sum of both bodyweight and stool scores, used as an overall measure of the 
progression of the DSS-induced ulcerative colitis model. Bars represent mean values ± SEM 
(n=10). Statistical analysis was performed by 2-way ANOVA (*** = p < 0.001, ** = p < 0.01, * = p 
< 0.05). 
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Supplementary Figure VIII. The expression of a Cre-PF4 promoter does not alter platelet-
leukocyte interactions. Whole blood isolated from Cre-PF4- and Cre-PF4+ mice was subject to 
RBC lysis before stimulation with various concentrations of CRP-XL for 10 min. Samples were 
then stained with PE-conjugated anti-CD45 and FITC-conjugated anti-CD41. IgG antibody 
controls were used to generate quadrants determining specific antibody binding within the 
leukocyte population. Data are mean values ± SEM (n=3). Statistical analysis was performed by 
2-way ANOVA with Bonferroni’s post-hoc test, with no significant alteration in response observed. 
 
